SAB Biotherapeutics (Big Cypress Acquisition) ^{Priced, Nasdaq: SABS}

We are a newly organized, blank check company. While we may acquire a target business in any industry or sector, we intend to focus on life science companies in the United States and Israel that complement our management team’s background and proprietary network. We believe the life sciences industry is attractive for a number of reasons. We believe that our management team is well positioned to identify opportunities in the life sciences sector. Through our management’s extensive industry relationships, we expect to have proprietary deal flow from our network of venture capital firms, private and public corporate clients, investment banking partners and existing investor referrals, essential in sourcing and vetting potential business combinations. Given our management team’s profile and dedicated industry approach, we anticipate that potential target businesses may also be brought to our attention from various sources outside of our network. We believe that our management’s reputation, with relationships across the life sciences industry and a track record of raising capital for first in class and best in class companies will enable us to become an ideal partner for potential targets in our preferred sector.